Gefitinib: current and future status in cancer therapy.

Clinical advances in hematology & oncology : H&O

Volumn 1, Issue 8, 2003, Pages 466-472

  Herbst, Roy S ^a   Kies, Merrill S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STATISTICS;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG EVALUATION; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33644793664     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)